Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : MRTX crawled time : 13:00 save search
Corcept Appoints Roberto Vieira as President, Oncology
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
CORT | News | $22.48 -2.26% -2.31% 1.1M
|
Health Technology
|
| O: 0.6%
H: 2.48%
C: 2.48%
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Published: 2024-01-10 (Crawled : 13:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.02%
H: 0.17%
C: -0.19%
krasg12 lung cancer cell treatment advanced
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
XYF | News | $3.815 -1.74% 0.39% 5.4K
|
Finance
|
| O: -3.19%
H: 4.87%
C: 4.87%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -4.68%
H: 2.46%
C: -1.83%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.16%
H: 0.47%
C: 0.2%
financial results
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation
Published: 2022-10-12 (Crawled : 13:00) - biospace.com/
AADI | $1.79 -2.72% -2.79% 110K
|
Manufacturing
|
| O: 3.7%
H: 0.0%
C: -7.64%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.14%
H: 5.61%
C: 5.46%
lung therapeutics tumors bioscience cancer
Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2021 and Recent Corporate Updates on February 28, 2022
Published: 2022-02-14 (Crawled : 13:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: -1.26%
financial results therapeutics report results
Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers
Published: 2021-11-17 (Crawled : 13:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.02%
H: 0.86%
C: -1.77%
new drug food application cancer drug submission
Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition
Published: 2021-06-28 (Crawled : 13:00) - biospace.com/
A | $137.49 -1.23% -0.36% 1.6M
|
Health Technology
|
| O: 0.24%
H: 0.28%
C: 0.2%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.38%
H: 5.43%
C: 3.42%
acquired bioscience
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.